A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

This study is testing a new type of cancer treatment called CAR-T cell therapy (a therapy where your own immune cells are engineered to attack cancer) that targets a protein called Cadherin-17 (CDH17) found on certain gastrointestinal tumors. **You may be eligible if...** - You have been diagnosed with one of the following cancers: gastric (stomach) adenocarcinoma, colon or rectal adenocarcinoma, or certain neuroendocrine tumors of the GI tract - Your cancer has returned or stopped responding to prior therapies - You are 18 years or older with adequate organ function - Tumor tissue samples are available for testing **You may NOT be eligible if...** - You have active brain metastases - You have significant autoimmune conditions or are on immunosuppressive therapy - You have active serious infections - You have severe heart, liver, or kidney problems Talk to your doctor to see if this trial is right for you.